Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4508-4513

  Yen, Li Chen ^a,d   Yeh, Yung Sung ^c   Chen, Chao Wen ^c   Wang, Hwei Ming ^e   Tsai, Hsiang Lin ^b,c,d   Lu, Chien Yu ^a,c   Chang, Yu Tang ^c   Chu, Koung Shing ^a,c   Lin, Shiu Ru ^d,f   Wang, Jaw Yuan ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d FOOYIN UNIVERSITY   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MOLECULAR MARKER; OXALIPLATIN;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEMBRANE ARRAY; METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67650366758     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3179     Document Type: Article

References (27)

1. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and5 -fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). EurJCancer 2001;37:1000 -5.
2. Teufel A, Steinmann S, SieblerJ, et al. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMCCancer 2004;4:38.
3. FolprechtG,LutzMP,Scho« ffskiP,etal.Cetuximaband irinotecan/5-fluorouracil/folinic acidis a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.AnnOncol 2006;17:450-6.
4. Recchia F, Candeloro G, Necozione S, Bratta M, Biseqna R, Rea S. Alternating XELFOX andX ELFIRI in patients with metastatic colorectal cancer. Am J Clin Oncol 2008;31:323-8.
5. Lie' vreA, BachetJB, Le CorreD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
6. Di Fiore F, BlanchardF , Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treatedb y cetuximab plus chemotherapy. BrJCancer 2007;96:1166-9.
7. Khambata-FordS , Garrett CR, Meropol NJ, et al. Expression of epiregulin anda mphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treatedwi th cetuximab. JClin Oncol 2007;25:3230 -7.
8. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associatedt o early radiological response in metastatic colorectal cancer treatedw ith cetuximab. Ann Oncol 2008;19:508-5.
9. Lie' vre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. JClin Oncol 2008;26:374- 9.
10. VanCutsemE, Lang I, D'haensG, et al. KRAS status andef ficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treatedwi th FOLFIRI with or without cetuximab: the CRYSTAL experience. JClin Oncol 2008;26:5s (suppl, abstr 2).
11. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status ande fficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008;26:178s (suppl, abstr 4000).
12. Di Fiore F, Charbonnier F, Lefebure B, et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008;99:551- 2.
13. ChenYF,Wang JY,Wu CH, Chen FM, ChengTL, Lin SR. Detection of circulating cancer cellswith K-ras oncogene using membrane array. Cancer Lett 2005; 229:115- 22.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solidtumo rs. European Organization for Research andTreatment of Cancer, National Cancer Institute of the UnitedS tates, National Cancer Institute of Canada. JNatl Cancer Inst 2000;92:205-16.
15. Chomczynski P, Sacchi N. Single-step methodof RNA isolation by acidgu anidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162: 156 - 9.
16. Sambrook J, Fritsch EF, ManiatisT. Molecular cloning: a laboratory manual. NewYork: ColdS pring Harbor Laboratory; 1989. p. 6.22 - 6.34.
17. WangJY, HsiehJS, Chen FM, et al. High frequency of activated K-ras codon 15 mutants in colorectal carcinomas fromTaiwanese patients. Int J Cancer 2003; 107:387 - 93.
18. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. JClin Oncol 2004;22:1201-8.
19. Cunningham D, HumbletY, Siena S, et al. Cetuximab monotherapy andc etuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2 004;351:337-45.
20. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
21. Hebbar M,Wacrenier A, Desauw C, et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006;17:855-7.
22. MessersmithWA, Ahnen DJ.Targeting EGFR in colorectal cancer. NEngl JMed20 08;359:1834-6.
23. Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of the APC, K-ras, andp5 3 mutations in the serum of colorectal cancer patients as circulating biomarkers. WorldJ Surg 2004;28:721-6.
24. Hsieh JS, Lin SR, Chang MY, et al. APC, K-ras, andp 53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features andp ostoperative surveillance. Am Surgeon 2005; 71:336 - 43.
25. Wang JY,Yeh CS, ChenYF, et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral bloodof Taiwanese patients with colorectal cancer. Int JMol Med2 006;17:737-47.
26. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis. Int JCancer1992;52:30-33.
27. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS andB RAF in primary and matchedme tastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217- 9.